These three words are used loosely in conversation but mean distinct things in the industry. Getting them straight is the foundation for everything else, because the entire competitive landscape is organised around which of them a company actually supplies.
Figure 1.1 — The build-up from a molecule to a finished tablet. Each step adds a layer of engineering and a layer of value — and the excipient supplier's job is to make one of those steps unnecessary. Direct compression skips the middle step entirely — and pays for it in the powder.
The active pharmaceutical ingredient is the substance with the therapeutic effect. It is what the patent covers, what the regulator's efficacy review is about, and what the drug is named after. It is also, very often, a difficult powder: sticky, poorly flowing, electrostatic, and present in quantities far too small to press into a tablet on its own. A 5 mg tablet of API would be invisible. The industry that makes APIs is a different industry — different chemistry, different capital intensity, different customers — and it is not the subject of this report.
An excipient is any component of the finished dosage form other than the active. Fillers, binders, disintegrants, lubricants, glidants, coatings, colours, preservatives. The old term was "inactive ingredient," and the old assumption was that these were inert bulking agents bought on price. That assumption is obsolete. A modern excipient is specified on a dozen physical parameters and is chosen because of how it behaves, not what it is made of. This report is about the largest and most technically interesting family of them: cellulosics, and above all microcrystalline cellulose (MCC).
A formulation is the specific combination of API and excipients, at specific grades and ratios, manufactured by a specific process. This is the crucial point: a formulation is not a recipe, it is a recipe plus a method. Change the grade of filler and you have changed the formulation, even if the ingredient list reads identically. That single fact is the source of the entire commercial moat described in Section 7.
| Term | What it is | Regulatory status | Bought by | Difficulty |
|---|---|---|---|---|
| API | The therapeutic molecule | Approved as part of the drug; own DMF | Formulators, CDMOs | High (chemistry) |
| Excipient | Every other component | No standalone approval — qualified inside the drug | Formulators, CDMOs | Low to very high |
| Formulation | Recipe + process + grades | The thing actually approved | Patients, via the brand | High (integration) |
Table 1.1 — The three core terms. Adjacent terms worth knowing: a grade is one supplier's specific particle specification of a material; a monograph is a pharmacopoeia's minimum quality standard for it; a DMF is the confidential process dossier filed with a regulator; and a CDMO is a contract manufacturer that formulates on someone else's behalf.
If it is on the label as the drug, it is an API. If it is in the tablet but not on the front of the box, it is an excipient. If changing it would require refiling paperwork with a regulator, it is part of the formulation — and that is nearly always true, which is why excipient suppliers are so rarely swapped.
This is not merely terminology. Which of the three a company touches determines almost everything about its economics. A firm that makes bulk cellulose powder competes in a commodity-but-massive business where pulp-buying efficiency and energy cost win. A firm that makes pharmaceutical-grade MCC competes on particle reproducibility and on a regulatory dossier that takes years to build. And a firm that makes co-processed, engineered excipient systems competes on a scarce formulation-science capability that keeps most rivals out entirely.
Keep this triad in mind as a lens. Every company profiled later in this report is, at heart, a particular mix of these three activities — and the most important strategic move in the whole sector, repeated again and again, is a company trying to shift its mix from the easy, crowded end toward the hard, defended end. The rest of the report simply gives you the science to understand why that shift is so hard, and the numbers to see who is winning it.
1 · What does it make? — technical powder, pharma-grade MCC, functional derivative, or engineered system.
2 · How hard is that to make? — which really means: how far up the particle-control and documentation problem does it reach.
3 · Why does it earn the margin it earns? — grade mix, customer qualification depth, or commodity scale.
These three questions, asked repeatedly, are the entire analytical toolkit of this report. Everything that follows is built to let you answer them on sight.
A useful sub-distinction inside "excipient" is between bulk and functional roles. A bulk excipient is there to occupy volume. A functional excipient is there to do something measurable — swell, dissolve, lubricate, retard release, mask taste. The line matters commercially because functional excipients are specified more tightly, qualified more carefully and priced far better. Microcrystalline cellulose is unusual in that it is used as both: it is the industry's default bulk filler and, at the right grade, a genuinely functional binder. That dual identity is why a single material anchors an entire sub-sector.
